William Blair analyst Tim Lugo is out defending Biohaven Pharmaceutical Holding (NYSE: BHVN) on weakness after the company agreed to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE